Masimo Reports Third Quarter 2022 Financial Results
Masimo (NASDAQ: MASI) reported a strong performance for Q3 2022, with consolidated revenue reaching $549.3 million, up 78.7% from $307.4 million in Q3 2021. Healthcare revenue was $327.2 million, reflecting 6.4% growth, while non-healthcare revenue stood at $222.1 million. GAAP net income was $37.9 million ($0.70 per diluted share), with non-GAAP net income at $53.9 million ($1.00 per diluted share). For Q4 2022, Masimo updated its guidance to $581 million to $611 million in revenue.
- Consolidated revenue increased by 78.7% year-over-year.
- Healthcare revenue grew by 6.4%, and 10% in constant currency.
- Non-GAAP net income of $53.9 million reflects strong operational performance.
- Fourth quarter revenue guidance is set between $581 million and $611 million.
- GAAP net income decreased from $57.8 million in Q3 2021 to $37.9 million in Q3 2022.
Third Quarter 2022 Highlights
-
Consolidated revenue was
$549 million -
Healthcare revenue was
$327 million 6% reported growth and10% constant currency growth; and -
Non-healthcare revenue was
$222 million
Third Quarter 2022 Financial Results
Consolidated revenue was
Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 76,100.
For the third quarter of 2022, on a consolidated basis, GAAP net income was
For additional financial details, please visit the Investor Relations section of the Company’s website at investor.masimo.com to access the third quarter 2022 Earnings Presentation materials.
Fourth Quarter 2022 and Full Year 2022 Financial Guidance
The Company provided the following estimates for its fourth quarter and full year 2022 guidance:
|
|
Fourth Quarter 2022 Guidance(1) |
|
Updated Full Year 2022 Guidance(1) |
||||
(in millions, except earnings per diluted share) |
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
Consolidated revenue |
|
|
|
|
|
|
|
|
Healthcare revenue |
|
|
|
|
|
|
|
|
Non-healthcare revenue |
|
|
|
|
|
|
|
|
Consolidated earnings per diluted share |
|
|
|
|
|
|
|
|
| ______________ | ||||||||
(1) Guidance provided |
||||||||
-
For our healthcare segment, our fourth quarter 2022 and full year 2022 revenue guidance includes year-over-year foreign currency headwinds of
$13.6 million $35.0 million
Supplementary Non-GAAP Financial Information
For additional non-GAAP financial details, please visit the Investor Relations section of the Company’s website at investor.masimo.com to access Supplementary Financial Information.
Non-GAAP Financial Measures
The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with
Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.
The Company has presented the following non-GAAP measures to assist investors in understanding the Company’s net operating results on an on-going basis: (i) constant currency product revenue growth %, (ii) non-GAAP net income, (iii) non-GAAP (net income) earnings per diluted share and (iv) non-GAAP operating income/margin. These non-GAAP financial measures may also assist investors in making comparisons of the Company’s operating results with those of other companies. Management believes constant currency product revenue growth, non-GAAP operating income/margin, non-GAAP net income and non-GAAP earnings per diluted share are important measures in the evaluation of the Company’s performance and uses these measures to better understand and evaluate our business.
The non-GAAP financial measures reflect adjustments for the following items:
Constant currency revenue adjustments
Some of our sales agreements with foreign customers provide for payment in currencies other than the
Acquisition, integration and related costs
These transactions represent gains, losses, and other related costs associated with acquisitions, integrations, investments, divestitures, assets impairments, and in-process research and development.
Acquired tangible asset amortization
These transactions represent amortization expense in connection with business or assets acquisitions associated with acquired tangible assets and asset valuation step-ups.
Acquired intangible asset amortization
These transactions represent amortization expense in connection with business or assets acquisitions associated with acquired intangible assets including, but not limited to customer relationships, intellectual property, trade names and non-competition agreements.
Litigation related expenses, settlements and awards
These transactions represent gains, losses, and other related costs associated with certain litigation matters, which can vary in their characteristics, frequency and significance to our operating results.
Other adjustments
In the event there are gains, losses and other adjustments which impact period-to-period comparability and do not represent the underlying ongoing results of the business, the Company may choose to exclude these from non-GAAP earnings.
Realized and unrealized gains or losses
These transactions represent gains, losses, and other related costs associated with foreign currency denominated transactions and investments. Changes in the underlying currency rates relative to the
Tax impact of non-GAAP adjustments
In order to reflect the tax effected impact of the non-GAAP adjustments, the Company will adjust the non-GAAP earnings by the approximate tax impact of these adjustments.
Excess tax benefits from stock-based compensation expense
GAAP requires that excess tax benefits recognized on stock-based compensation expense be reflected in our provision for income taxes rather than paid-in capital. As these excess tax benefits may be highly variable from period-to-period, the Company may choose to exclude these tax benefits from non-GAAP earnings to facilitate comparability between periods and with peers.
Financing related adjustments
The Company may enter into various financial arrangements whereby costs are incurred and certain instrument features are valued and expensed accordingly but are not necessarily indicative of the on-going cash flow generation of the Company and therefore excludes these costs from non-GAAP earnings. For GAAP earnings per diluted share purposes, the Company cannot reflect the anti-dilutive impact, if applicable, in its diluted shares calculations. However, the Company believes that reflecting the anti-dilutive impact of these instruments in non-GAAP earnings per diluted share provides management and investors with useful information in evaluating the financial performance of the Company on a per share basis.
Third Quarter 2022 Actuals versus Third Quarter 2021 Actuals
RECONCILIATION OF HEALTHCARE GAAP TO NON-GAAP CONSTANT CURRENCY REVENUE(1): |
|||||||
|
Three Months Ended |
||||||
(in millions, except percentages) |
|
|
|||||
GAAP healthcare revenue |
$ |
327.2 |
|
$ |
307.4 |
||
Constant currency revenue adjustments |
|
11.1 |
|
|
N/A |
||
Non-GAAP healthcare constant currency revenue |
$ |
338.3 |
|
$ |
307.4 |
||
GAAP healthcare revenue growth |
|
6.4 |
% |
|
|||
Non-GAAP healthcare constant currency revenue growth % |
|
10.0 |
% |
|
|||
| __________________ | |||||||
(1) May not foot due to rounding. |
|||||||
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET INCOME PER DILUTED SHARE(1): |
||||||||||||||||
|
|
Three Months Ended |
||||||||||||||
|
|
|
|
|
||||||||||||
(in millions, except per diluted share amounts) |
|
$ |
|
Per Diluted Share |
|
$ |
|
Per Diluted Share |
||||||||
GAAP net income |
|
$ |
37.9 |
|
|
$ |
0.70 |
|
|
$ |
57.8 |
|
|
$ |
1.00 |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
||||||||
Acquired tangible asset amortization |
|
|
8.8 |
|
|
|
0.16 |
|
|
|
0.1 |
|
|
|
— |
|
Acquired intangible asset amortization |
|
|
4.6 |
|
|
|
0.09 |
|
|
|
1.5 |
|
|
|
0.03 |
|
Acquisition, integration and related costs |
|
|
9.7 |
|
|
|
0.18 |
|
|
|
0.3 |
|
|
|
0.01 |
|
Litigation related expenses, settlements and awards |
|
|
3.4 |
|
|
|
0.06 |
|
|
|
1.2 |
|
|
|
0.02 |
|
Other adjustments |
|
|
(0.4 |
) |
|
|
(0.01 |
) |
|
|
— |
|
|
|
— |
|
Realized and unrealized gains or losses |
|
|
(5.4 |
) |
|
|
(0.10 |
) |
|
|
0.2 |
|
|
|
— |
|
Financing related adjustments |
|
|
0.5 |
|
|
|
0.01 |
|
|
|
— |
|
|
|
— |
|
Tax impact of non-GAAP adjustments |
|
|
(4.9 |
) |
|
|
(0.09 |
) |
|
|
(0.5 |
) |
|
|
(0.01 |
) |
Excess tax benefits from stock-based compensation expense |
|
|
(0.3 |
) |
|
|
(0.01 |
) |
|
|
(6.4 |
) |
|
|
(0.11 |
) |
Total non-GAAP adjustments |
|
|
16.0 |
|
|
|
0.30 |
|
|
|
(3.5 |
) |
|
|
(0.06 |
) |
Non-GAAP net income |
|
$ |
53.9 |
|
|
$ |
1.00 |
|
|
$ |
54.3 |
|
|
$ |
0.94 |
|
Weighted average shares outstanding-diluted |
|
|
|
|
54.1 |
|
|
|
|
|
57.7 |
|
||||
| __________________ | ||||||||||||||||
(1) May not foot due to rounding. |
||||||||||||||||
Fourth Quarter 2022 and Full Year Financial Guidance
RECONCILIATION OF HEALTHCARE GAAP TO NON-GAAP CONSTANT CURRENCY REVENUE(1): |
||||
|
|
Guidance(2) |
||
(in millions, except percentages) |
|
Fourth Quarter
|
Full Year
|
|
GAAP healthcare revenue |
|
|
|
|
Constant currency revenue adjustments |
|
14 |
35 |
|
Non-GAAP healthcare constant currency revenue |
|
|
|
|
GAAP healthcare revenue growth % |
|
|
||
Non-GAAP healthcare constant currency revenue growth % |
|
|
||
| __________________ | ||||
(1) May not foot due to rounding. |
||||
(2) Guidance provided |
||||
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND NET INCOME PER DILUTED SHARE(1): |
||||||||
|
|
|
|
|||||
|
Guidance(2) |
|||||||
|
Fourth Quarter
|
Updated Full Year
|
||||||
(in millions, except per diluted share amounts) |
$ |
Per Diluted Share |
$ |
Per Diluted Share |
||||
GAAP net income |
|
|
|
|
||||
Non-GAAP adjustments: |
|
|
|
|
||||
Acquired tangible asset amortization |
2.3 |
0.04 |
59.4 |
1.07 |
||||
Acquired intangible asset amortization |
7.4 |
0.14 |
22.8 |
0.41 |
||||
Acquisition, integration and related costs |
4.7 |
0.09 |
37.2 |
0.67 |
||||
Litigation related expenses, settlements and awards |
6.6 |
0.12 |
22.6 |
0.41 |
||||
Other adjustments |
— |
— |
(0.9) |
(0.02) |
||||
Realized and unrealized gains or losses |
— |
— |
(12.9) |
(0.23) |
||||
Financing related adjustments |
0.5 |
0.01 |
1.5 |
0.03 |
||||
Tax impact of non-GAAP adjustments |
(4.9) |
(0.09) |
(31.9) |
(0.58) |
||||
Excess tax benefits from stock-based compensation expense |
— |
— |
(2.2) |
(0.04) |
||||
Total non-GAAP adjustments |
16.5 |
0.30 |
95.7 |
1.73 |
||||
Non-GAAP net income |
|
|
|
|
||||
Weighted average shares outstanding-diluted |
|
54.5 |
|
55.3 |
||||
| __________________ | ||||||||
(1) May not foot due to rounding. |
||||||||
(2) Guidance provided |
||||||||
Conference Call:
The conference call to review the results will begin at
To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID number.
Conference Call Registration Link:
https://conferencingportals.com/event/nUSpRIEm
A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.
About Masimo
Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22
ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our expectations for fourth quarter and full year 2022 financial guidance; the interest in our W1™ watch and upcoming innovations; our long-term outlook; demand for our products; anticipated revenue and earnings growth; our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies and reduce the cost of care; our ability to address supply chain challenges; anticipated benefits from our acquisition of Sound United; and demand for our technologies. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET® and Masimo rainbow SET™ products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; our ability to successfully integrate Sound United’s brands into our business; our ability to address and expand into new markets; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; our ongoing litigation and related matters; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in millions) |
|||||||
|
|
|
|
||||
ASSETS |
|
|
|
||||
Current assets |
|
|
|
||||
Cash and cash equivalents |
$ |
219.5 |
|
|
$ |
745.3 |
|
Accounts receivable, net of allowance for credit losses |
|
371.6 |
|
|
|
200.8 |
|
Inventories |
|
495.4 |
|
|
|
201.4 |
|
Other current assets |
|
159.1 |
|
|
|
91.0 |
|
Total current assets |
|
1,245.6 |
|
|
|
1,238.5 |
|
Lease receivable, noncurrent |
|
79.6 |
|
|
|
73.6 |
|
Deferred costs and other contract assets |
|
37.0 |
|
|
|
28.1 |
|
Property and equipment, net |
|
372.2 |
|
|
|
272.8 |
|
Customer relationships, net |
|
204.5 |
|
|
|
15.3 |
|
Acquired technologies, net |
|
163.9 |
|
|
|
19.7 |
|
Other intangible assets, net |
|
78.2 |
|
|
|
37.5 |
|
Trademarks |
|
262.0 |
|
|
|
— |
|
|
|
446.3 |
|
|
|
100.3 |
|
Deferred tax assets |
|
56.5 |
|
|
|
52.6 |
|
Other non-current assets |
|
110.6 |
|
|
|
48.6 |
|
Total assets |
$ |
3,056.4 |
|
|
$ |
1,887.0 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
||||
Current liabilities |
|
|
|
||||
Accounts payable |
$ |
267.8 |
|
|
$ |
75.5 |
|
Accrued compensation |
|
90.4 |
|
|
|
70.8 |
|
Deferred revenue and other contract liabilities, current |
|
77.6 |
|
|
|
50.9 |
|
Other current liabilities |
|
151.5 |
|
|
|
70.4 |
|
Total current liabilities |
|
587.3 |
|
|
|
267.6 |
|
Long-term debt |
|
951.4 |
|
|
|
— |
|
Deferred tax liabilities |
|
139.2 |
|
|
|
5.1 |
|
Other non-current liabilities |
|
125.9 |
|
|
|
64.0 |
|
Total liabilities |
|
1,803.8 |
|
|
|
336.7 |
|
Commitments and contingencies |
|
|
|
||||
Stockholders’ equity |
|
|
|
||||
Common stock |
|
0.1 |
|
|
|
0.1 |
|
|
|
(1,169.1 |
) |
|
|
(767.7 |
) |
Additional paid-in capital |
|
775.0 |
|
|
|
752.5 |
|
Accumulated other comprehensive loss |
|
(26.9 |
) |
|
|
(5.5 |
) |
Retained earnings |
|
1,673.5 |
|
|
|
1,570.9 |
|
Total stockholders’ equity |
|
1,252.6 |
|
|
|
1,550.3 |
|
Total liabilities and stockholders’ equity |
$ |
3,056.4 |
|
|
$ |
1,887.0 |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in millions, except per share amounts) |
|||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||
|
|
|
|
|
|
|
|
||||||
Revenue |
$ |
549.3 |
|
|
$ |
307.4 |
|
$ |
1,418.8 |
|
$ |
911.6 |
|
Cost of goods sold |
|
266.8 |
|
|
|
103.8 |
|
|
673.4 |
|
|
318.1 |
|
Gross profit |
|
282.5 |
|
|
|
203.6 |
|
|
745.4 |
|
|
593.5 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||
Selling, general and administrative |
|
174.6 |
|
|
|
100.6 |
|
|
471.6 |
|
|
291.2 |
|
Research and development |
|
53.1 |
|
|
|
35.4 |
|
|
137.1 |
|
|
103.9 |
|
Total operating expenses |
|
227.7 |
|
|
|
136.0 |
|
|
608.7 |
|
|
395.1 |
|
Operating income |
|
54.8 |
|
|
|
67.6 |
|
|
136.7 |
|
|
198.4 |
|
Non-operating (loss) income |
|
(2.8 |
) |
|
|
— |
|
|
1.0 |
|
|
(0.7 |
) |
Income before provision for income taxes |
|
52.0 |
|
|
|
67.6 |
|
|
137.7 |
|
|
197.7 |
|
Provision for income taxes |
|
14.1 |
|
|
|
9.8 |
|
|
35.1 |
|
|
36.3 |
|
Net income |
$ |
37.9 |
|
|
$ |
57.8 |
|
$ |
102.6 |
|
$ |
161.4 |
|
|
|
|
|
|
|
|
|
||||||
Net income per share: |
|
|
|
|
|
|
|
||||||
Basic |
$ |
0.72 |
|
|
$ |
1.05 |
|
$ |
1.90 |
|
$ |
2.93 |
|
Diluted |
$ |
0.70 |
|
|
$ |
1.00 |
|
$ |
1.85 |
|
$ |
2.80 |
|
|
|
|
|
|
|
|
|
||||||
Weighted-average shares used in per share calculations: |
|
|
|
|
|
|
|
||||||
Basic |
|
52.5 |
|
|
|
55.1 |
|
|
54.0 |
|
|
55.1 |
|
Diluted |
|
54.1 |
|
|
|
57.7 |
|
|
55.6 |
|
|
57.7 |
|
The following table presents details of the stock-based compensation expense that is included in each functional line item in the condensed consolidated statements of operations (in millions):
|
Three Months Ended |
|
Nine Months Ended |
||||||||||
|
|
|
|
|
|
|
|
||||||
Cost of goods sold |
$ |
0.3 |
|
$ |
0.3 |
|
$ |
0.8 |
|
$ |
0.6 |
||
Selling, general and administrative |
|
9.2 |
|
|
9.0 |
|
|
29.4 |
|
|
23.5 |
||
Research and development |
|
4.0 |
|
|
3.3 |
|
|
11.5 |
|
|
9.4 |
||
Total |
$ |
13.5 |
|
$ |
12.6 |
|
$ |
41.7 |
|
$ |
33.5 |
||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in millions) |
|||||||
|
Nine Months Ended |
||||||
|
|
|
|
||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
102.6 |
|
|
$ |
161.4 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
56.6 |
|
|
|
26.5 |
|
Stock-based compensation |
|
41.7 |
|
|
|
33.5 |
|
Gain on disposal of equipment, intangibles and other assets |
|
0.1 |
|
|
|
0.3 |
|
Provision for credit losses |
|
1.2 |
|
|
|
0.6 |
|
Amortization of debt issuance cost |
|
0.9 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Increase in accounts receivable |
|
(66.7 |
) |
|
|
(51.0 |
) |
(Increase) decrease in inventories |
|
(71.0 |
) |
|
|
12.3 |
|
Decrease in other current assets |
|
11.7 |
|
|
|
4.4 |
|
Increase in lease receivable, net |
|
(5.9 |
) |
|
|
(9.3 |
) |
Increase in deferred costs and other contract assets |
|
(31.6 |
) |
|
|
(2.6 |
) |
(Increase) decrease in other non-current assets |
|
(22.2 |
) |
|
|
0.1 |
|
Increase (decrease) in accounts payable |
|
69.6 |
|
|
|
(4.3 |
) |
Decrease in accrued compensation |
|
(6.9 |
) |
|
|
(1.3 |
) |
Decrease in accrued liabilities |
|
(26.5 |
) |
|
|
(4.0 |
) |
Decrease in income tax payable |
|
(8.4 |
) |
|
|
(1.5 |
) |
Increase in deferred revenue and other contract-related liabilities |
|
19.7 |
|
|
|
1.4 |
|
(Decrease) increase in other non-current liabilities |
|
(28.9 |
) |
|
|
0.6 |
|
Net cash provided by operating activities |
|
36.0 |
|
|
|
167.1 |
|
Cash flows from investing activities: |
|
|
|
||||
Purchases of property and equipment, net |
|
(36.0 |
) |
|
|
(20.7 |
) |
Increase in intangible assets |
|
(13.9 |
) |
|
|
(8.2 |
) |
Business combinations, net of cash acquired |
|
(985.0 |
) |
|
|
— |
|
Other strategic investing activities |
|
— |
|
|
|
(2.6 |
) |
Net cash used in investing activities |
|
(1,034.9 |
) |
|
|
(31.5 |
) |
Cash flows from financing activities: |
|
|
|
||||
Borrowings under line of credit |
|
1,050.6 |
|
|
|
— |
|
Repayments on line of credit |
|
(96.3 |
) |
|
|
— |
|
Debt issuance costs |
|
(9.3 |
) |
|
|
— |
|
Proceeds from issuance of common stock |
|
6.9 |
|
|
|
19.0 |
|
Payroll tax withholdings on behalf of employees for vested equity awards |
|
(25.4 |
) |
|
|
(16.7 |
) |
Repurchases of common stock |
|
(401.4 |
) |
|
|
(128.9 |
) |
Net cash provided by (used in) financing activities |
|
525.1 |
|
|
|
(126.6 |
) |
Effect of foreign currency exchange rates on cash |
|
(52.5 |
) |
|
|
(0.1 |
) |
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
(526.3 |
) |
|
|
8.9 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
748.4 |
|
|
|
645.0 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
222.1 |
|
|
$ |
653.9 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006146/en/
Investor Contact:
(949) 297-7077
ekammerman@masimo.com
Media Contact:
(949) 396-3376
elamb@masimo.com
Source: Masimo
FAQ
What were Masimo's Q3 2022 earnings?
How did healthcare revenue perform in Q3 2022 for Masimo?
What is Masimo's revenue guidance for Q4 2022?
What is Masimo's non-GAAP net income for Q3 2022?
